Open AccessNilotinib As Front-Line Treatment for Patients With Chronic Myeloid Leukemia in Early Chronic Phase
Author(s) -
Jörge E. Cortes,
Dan Jones,
Susan O’Brien,
Elias Jabbour,
Marina Konopleva,
Alessandra Ferrajoli,
Tapan M. Kadia,
Gautam Borthakur,
Denise Stigliano,
Jianqin Shan,
Hagop M. Kantarjian
Publication year - 2009
Publication title -
journal of clinical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 10.482
H-Index - 548
eISSN - 1527-7755
pISSN - 0732-183X
DOI - 10.1200/jco.2009.25.4896
Subject(s) - medicine , nilotinib , myeloid leukemia , imatinib , neutropenia , imatinib mesylate , surgery , chronic toxicity , toxicity
Although most patients with chronic myeloid leukemia (CML) in chronic phase respond well to front-line therapy with imatinib, some patients do not achieve the desirable end point, and others may eventually lose response or are intolerant.
Accelerating Research
Robert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom
Address
John Eccles HouseRobert Robinson Avenue,
Oxford Science Park, Oxford
OX4 4GP, United Kingdom